keyword
MENU ▼
Read by QxMD icon Read
search

phase 3 carcinoma

keyword
https://www.readbyqxmd.com/read/29031202/targeting-of-cell-cycle-and-let-7a-stat3-pathway-by-niclosamide-inhibits-proliferation-migration-and-invasion-in-oral-squamous-cell-carcinoma-cells
#1
Xiaoxu Li, Ruiyu Ding, Zewen Han, Zeyun Ma, Yixiang Wang
The low median survival rate of oral squamous cell carcinoma (OSCC) is associated with chemotherapeutic resistance. Niclosamide is an oral anti-helminthic drug, its anti-cancer effect has been reported in recent years. However, the effect of niclosamide on OSCC remains largely unknown. In this study, we, for the first time, investigated the underlying mechanisms from cell cycle arrest and let-7a/STAT3 axis through CCK-8, cell cycle, apoptosis, wound healing, Transwell invasion, generation of stable cell line, real-time PCR, and western blot assays using two OSCC cell lines WSU-HN6 and Tca83...
October 11, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29024937/protein-biomarkers-predictive-for-response-to-anti-egfr-treatment-in-ras-wild-type-metastatic-colorectal-carcinoma
#2
Astrid Lièvre, Bérèngere Ouine, Jim Canet, Aurélie Cartier, Yael Amar, Wulfran Cacheux, Odette Mariani, Rosine Guimbaud, Janick Selves, Thierry Lecomte, Serge Guyetant, Ivan Bieche, Frédérique Berger, Leanne de Koning
BACKGROUND: Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance. However, even among RAS wild-type (WT) patients, only a fraction responds to anti-EGFR therapy, suggesting that other mechanisms of resistance exist. We hypothesise that different (epi)genetic alterations can lead to primary anti-EGFR resistance and that the crucial end point is the activation of protein signalling pathways...
October 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29023148/nonstandardized-terminology-to-describe-focal-liver-lesions-in-patients-at-risk-for-hepatocellular-carcinoma-implications-regarding-clinical-communication
#3
Michael T Corwin, Andrew Y Lee, Ghaneh Fananapazir, Thomas W Loehfelm, Souvik Sarkar, Claude B Sirlin
OBJECTIVE: The purpose of this study is to determine the correlation between malignancy risk of focal liver observations in patients at risk for hepatocellular carcinoma (HCC) implied by phrases used in nonstructured radiology reports with the risk inferred by hepatologists. MATERIALS AND METHODS: We performed a retrospective review of nonstructured radiology reports issued before Liver Imaging and Reporting Data System (LI-RADS) adoption from four-phase liver CT examinations of patients at risk for HCC...
October 12, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29019283/antitumor-effectiveness-and-mechanism-of-action-of-ru-ii-amino-acid-diphosphine-complexes-in-the-peritoneal-carcinomatosis-progression
#4
Francyelli Mello-Andrade, Wanderson Lucas da Costa, Wanessa Carvalho Pires, Flávia de Castro Pereira, Clever Gomes Cardoso, Ruy de Souza Lino-Junior, Vicente Raul Chavarria Irusta, Cristiene Costa Carneiro, Paulo Roberto de Melo-Reis, Carlos Henrique Castro, Marcio Aurélio Pinheiro Almeida, Alzir Azevedo Batista, Elisângela de Paula Silveira-Lacerda
Peritoneal carcinomatosis is considered as a potentially lethal clinical condition, and the therapeutic options are limited. The antitumor effectiveness of the [Ru(l-Met)(bipy)(dppb)]PF6(1) and the [Ru(l-Trp)(bipy)(dppb)]PF6(2) complexes were evaluated in the peritoneal carcinomatosis model, Ehrlich ascites carcinoma-bearing Swiss mice. This is the first study that evaluated the effect of Ru(II)/amino acid complexes for antitumor activity in vivo. Complexes 1 and 2 (2 and 6 mg kg(-1)) showed tumor growth inhibition ranging from moderate to high...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29018051/phase-iii-heat-study-adding-lyso-thermosensitive-liposomal-doxorubicin-to-radiofrequency-ablation-in-patients-with-unresectable-hepatocellular-carcinoma-lesions
#5
Won Young Tak, Shi-Ming Lin, Yijun Wang, Jiasheng Zheng, Aldo Vecchione, Soo Young Park, Min Hua Chen, Stephen Wong, Ruocai Xu, Cheng-Yuan Peng, Yi-You Chiou, Guan-Tarn Huang, Jianqiang Cai, Basri Johan Abdullah, June Sung Lee, Jae Young Lee, Jong Young Choi, Julieta Gopez-Cervantes, Morris Sherman, Richard S Finn, Masao Omata, Michael O'Neal, Lukas Makris, Nicholas Borys, Ronnie Poon, Riccardo Lencioni
PURPOSE: Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of doxorubicin contained within a heat-sensitive liposome. When heated to >=40ºC, LTLD locally releases a high concentration of doxorubicin. We aimed to determine whether adding LTLD improves the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) lesions with a maximum diameter (dmax) of 3 to 7 cm. PATIENTS AND METHODS: The HEAT Study was a randomized, double-blind, dummy-controlled trial of RFA +/- LTLD...
October 10, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28990511/sunitinib-in-the-treatment-of-thyroid-cancer
#6
Ferrari Silvia Martinaa, Centanni Marco, Virili Camilla, Miccoli Mario, Ferrari Paola, Ruffilli Ilaria, Ragusa Francesca, Antonelli Alessandro, Fallahi Poupak
BACKGROUND: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors...
October 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28990045/anti%C3%A2-tumor-effects-of-bakuchiol-on-human-gastric-carcinoma-cell-lines-are-mediated-through-pi3k-akt-and-mapk-signaling-pathways
#7
Long Lv, Bo Liu
Bakuchiol is extracted from Psoralea corylifolia, a member of the Leguminosae family, has been used in Indian Ayurvedic and Chinese traditional medicine, and it possesses an anticancer effect. The primary aim of the present study was to identify the molecular mechanisms underlying the anticancer effect of bakuchiol monoterpenes. Bakuchiol treatment significantly inhibited NUGC3 human gastric cancer cell viability in a concentration dependent manner. In addition, bakuchiol significantly increased the apoptotic cell population in the sub‑G1 phase, and Annexin‑V‑fluorescein isothiocyanate/propidium iodide double staining confirmed the increase in apoptosis...
October 3, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28988687/orantinib-versus-placebo-combined-with-transcatheter-arterial-chemoembolisation-in-patients-with-unresectable-hepatocellular-carcinoma-oriental-a-randomised-double-blind-placebo-controlled-multicentre-phase-3-study
#8
Masatoshi Kudo, Ann-Lii Cheng, Joong-Won Park, Jae Hyung Park, Po-Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I-Shyan Sheen, Chang-Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai
BACKGROUND: Orantinib is an oral multi-kinase inhibitor. This study was done to evaluate the efficacy of orantinib combined with conventional transcatheter arterial chemoembolisation (cTACE) in patients with unresectable hepatocellular carcinoma. METHODS: This randomised, double-blind, placebo-controlled, phase 3 study was done at 75 sites in Japan, South Korea, and Taiwan. Patients with unresectable hepatocellular carcinoma, no extra-hepatic tumour spread, and Child-Pugh score of 6 or less were randomly assigned (1:1) by interactive web response system using a computer-generated sequence to receive orantinib or placebo, within 28 days of cTACE...
October 4, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28987693/association-between-non-hypervascular-hypointense-nodules-on-gadoxetic-acid-enhanced-mri-and-liver-stiffness-or-hepatocellular-carcinoma
#9
Jeong Ah Hwang, Tae Wook Kang, Young Kon Kim, Seong Hyun Kim, Yong Han Paik, Sang Yun Ha, Seonwoo Kim
PURPOSE: To assess the association between non-hypervascular hypointense nodules (NHHNs) on gadoxetic acid-enhanced magnetic resonance imaging (MRI) and liver stiffness (LS) in patients with chronic liver disease, and analyzed their progression to overt hepatocellular carcinoma (HCC). METHODS: Between August 2012 and March 2016, a total of 714 consecutive patients who had undergone transient elastography for LS measurement and gadoxetic acid-enhanced MRI were investigated...
October 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28987671/dual-energy-spectral-ct-imaging-for-the-evaluation-of-small-hepatocellular-carcinoma-microvascular-invasion
#10
Chuang-Bo Yang, Shuang Zhang, Yong-Jun Jia, Yong Yu, Hai-Feng Duan, Xi-Rong Zhang, Guang-Ming Ma, Chenglong Ren, Nan Yu
OBJECTIVE: To study the clinical value of dual-energy spectral CT in the quantitative assessment of microvascular invasion of small hepatocellular carcinoma. METHODS: This study was approved by our ethics committee. 50 patients with small hepatocellular carcinoma who underwent contrast enhanced spectral CT in arterial phase (AP) and portal venous phase (VP) were enrolled. Tumour CT value and iodine concentration (IC) were measured from spectral CT images. The slope of spectral curve, normalized iodine concentration (NIC, to abdominal aorta) and ratio of IC difference between AP and VP (RICAP-VP: [RICAP-VP=(ICAP-ICVP)/ICAP]) were calculated...
October 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28982907/hypofractionated-postoperative-imrt-in-prostate-carcinoma-a-phase-i-ii-study
#11
Gabriella Macchia, Giambattista Siepe, Ilaria Capocaccia, Nam P Nguyen, Riccardo Schiavina, Silvia Cammelli, Sara Guerri, Alessandra Arcelli, Milly Buwenge, Maria Ntreta, Savino Cilla, Vincenzo Valentini, Francesco Deodato, Alessio G Morganti
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982752/urothelial-carcinoma-of-the-bladder-and-the-rise-of-immunotherapy
#12
REVIEW
David D Chism
With the advent of platinum-based chemotherapy, survival rates for metastatic urothelial carcinoma have plateaued, giving way to the modern immunotherapy paradigm. Although immunotherapy as an effective treatment dates back to the live, attenuated bacillus Calmette-Guérin vaccine, the recent impact of immune checkpoint inhibitors targeting programmed death/programmed death-ligand 1 (PD-1/PD-L1) coupled with the promise of both anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies and indoleamine-2, 3-dioxygenase-1 (IDO-1) inhibitors have provided a resurgence...
October 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28977909/2-acetylamino-3-4-2-acetylamino-2-carboxyethylsulfanylcarbonylamino-phenyl-carbamoylsulfanyl-propionic-acid-a-glutathione-reductase-inhibitor-induces-g2-m-cell-cycle-arrest-through-generation-of-thiol-oxidative-stress-in-human-esophageal-cancer-cells
#13
Xia Li, Zhiming Jiang, Jianguo Feng, Xiaoying Zhang, Junzhou Wu, Wei Chen
Esophageal squamous cell carcinoma (ESCC) is a highly malignant cancer with poor response to both of chemotherapy and radiotherapy. 2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino) phenyl carbamoylsulfanyl] propionic acid (2-AAPA), an irreversible inhibitor of glutathione reductase (GR), is able to induce intracellular oxidative stress, and has shown anticancer activity in many cancer cell lines. In this study, we investigated the effects of 2-AAPA on the cell proliferation, cell cycle and apoptosis and aimed to explore its mechanism of action in human esophageal cancer TE-13 cells...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28975831/stereotactic-body-radiation-therapy-for-hepatocellular-carcinoma-and-intrahepatic-cholangiocarcinoma
#14
Puja S Venkat, Sarah E Hoffe, Jessica M Frakes
The role of external beam radiation therapy for primary liver malignancies has historically been limited due to the risk of radiation-induced liver disease. However, with the advent of stereotactic body radiotherapy (SBRT), we are able to dose escalate while safely sparing critical nearby structures. This review explores the evidence surrounding the use of SBRT for the treatment of primary liver malignancies. A review of the literature was performed. This article discusses the challenges, efficacy, and safety of SBRT for primary liver malignancies in order to conceptualize its role within a multidisciplinary framework...
July 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28974748/cytological-assessments-and-transcriptome-profiling-demonstrate-that-evodiamine-inhibits-growth-and-induces-apoptosis-in-a-renal-carcinoma-cell-line
#15
Xiao-Long Yuan, Peng Zhang, Xin-Min Liu, Yong-Mei Du, Xiao-Dong Hou, Sen Cheng, Zhong-Feng Zhang
Chinese medicines are an important source of secondary metabolites with excellent antitumour activity. Evodia rutaecarpa, from the family Rutaceae, exhibits antitumour activity. Evodiamine (EVO), which was isolated from the fruit of E. rutaecarpa, exhibits robust antitumour activity. However, the antitumour mechanism of EVO remains unclear. In this study, we assessed the growth-inhibiting effect of EVO on two renal carcinoma cell lines. We found that EVO could change the morphology and decrease the viability and proliferation of cells in a time- and concentration-dependent manner in vitro...
October 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28972963/a-phase-1-study-of-arq-087-an-oral-pan-fgfr-inhibitor-in-patients-with-advanced-solid-tumours
#16
K P Papadopoulos, B F El-Rayes, A W Tolcher, A Patnaik, D W Rasco, R D Harvey, P M LoRusso, J C Sachdev, G Abbadessa, R E Savage, T Hall, B Schwartz, Y Wang, J Kazakin, W L Shaib
BACKGROUND: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose (RP2D). METHODS: Patients with advanced solid tumours received ARQ 087 administered initially at 25 mg every other day and dose-escalated from 25 to 425 mg daily (QD) continuous dosing. FGF19, 21, 23, and serum phosphate were assessed as potential biomarkers of target engagement...
October 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28969053/induction-of-socs3-by-liver-x-receptor-suppresses-the-proliferation-of-hepatocellular-carcinoma-cells
#17
Haojun Xiong, Yan Zhang, Shan Chen, Zhenhong Ni, Jintao He, Xinzhe Li, Bo Li, Kai Zhao, Fan Yang, Yijun Zeng, Bingbo Chen, Fengtian He
Liver X receptor (LXR), a member of nuclear receptor superfamily, is involved in the regulation of glucose, lipid and cholesterol metabolism. Recently, it has been reported that LXR suppress different kinds of cancers including hepatocellular carcinoma (HCC). However, the corresponding mechanism is still not well elucidated. In the present study, we found that activation of LXR downregulated cyclin D1 while upregulated p21 and p27 by elevating the level of suppressor of cytokine signaling 3 (SOCS3), leading to the cell cycle arrest at G1/S phase and growth inhibition of HCC cells...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28966729/arsenic-trioxide-induces-apoptosis-via-specific-signaling-pathways-in-ht-29-colon-cancer-cells
#18
Jacqueline J Stevens, Barbara Graham, Erika Dugo, Bezawit Berhaneselassie-Sumner, Kenneth Ndebele, Paul B Tchounwou
BACKGROUND: Arsenic trioxide (ATO) is highly effective in the treatment of patients with acute promyelocytic leukemia (APL). It is a chemotherapeutic agent that has been shown to induce apoptosis in several tumor cell lines. However, research into its effects on colon carcinoma cells is still very limited. We previously reported that ATO is cytotoxic and causes DNA damage in HT-29 human colorectal adenocarcinoma cells. In the present study, we further evaluated its effect on oxidative stress (OS), and examined its apoptotic mechanisms of action on HT-29 cells...
January 2017: Journal of Cancer Science & Therapy
https://www.readbyqxmd.com/read/28964539/gefitinib-for-patients-with-incurable-cutaneous-squamous-cell-carcinoma-a-single-arm-phase-ii-clinical-trial
#19
William N William, Lei Feng, Renata Ferrarotto, Lawrence Ginsberg, Merrill Kies, Scott Lippman, Bonnie Glisson, Edward S Kim
BACKGROUND: Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the efficacy of EGFR inhibitors in incurable, recurrent, and/or metastatic CSCC. OBJECTIVE: To determine the response rate to gefitinib in patients with CSCC not amenable to curative therapy including surgery or radiation. METHODS: This was a single-arm phase II study...
September 27, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28963790/phase-i-study-of-induction-chemotherapy-with-afatinib-ribavirin-and-weekly-carboplatin-and-paclitaxel-for-stage-iva-ivb-human-papillomavirus-associated-oropharyngeal-squamous-cell-cancer
#20
Lara A Dunn, Matthew G Fury, Eric J Sherman, Alan A Ho, Nora Katabi, Sofia S Haque, David G Pfister
BACKGROUND: The human papillomavirus (HPV) E6 oncoprotein enhances the oncogenic potential of ErbB proteins in HPV-related malignancies. This phase I study evaluates the addition of afatinib, an ErbB family inhibitor, and ribavirin to paclitaxel and carboplatin induction chemotherapy in HPV-associated, locally advanced oropharyngeal squamous cell carcinoma (SCC). METHODS: This dose escalation study included 2 doses of oral afatinib: 30 and 40 mg daily. Ribavirin dosing was weight based...
September 30, 2017: Head & Neck
keyword
keyword
91255
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"